Abstract

The global outbreak of the COVID-19 pandemic, caused by the SARS-CoV-2 virus, has spurred an urgent search for effective antiviral medications. Favipiravir (FVP), an antiviral medicine, has emerged as a promising solution to halt the replication and spread of the virus within the human body. In this comprehensive review, we delve into the molecular mechanisms of FVP, exploring its ability to combat the coronavirus family, with SARS-CoV-2 as the primary focus. The coronavirus family, notorious for causing respiratory illnesses ranging from the common cold to severe acute respiratory syndrome (SARS), poses a significant threat to global public health. FVP, known for its anti-viral properties, has garnered attention for its potential to address the COVID-19 crisis. This review meticulously examines the harmful effects associated with FVP, shedding light on its safety margins and the evolving understanding of its deteriorating state. Despite its popularity as a go-to anti-COVID-19 drug, it is crucial to understand the nuances surrounding FVP to optimize its usage and mitigate potential risks. As the world grapples with the ongoing pandemic, understanding the intricacies of FVP's efficacy and safety profile becomes paramount. This review aims to contribute to the growing body of knowledge surrounding FVP, providing insights that are vital for healthcare professionals, researchers, and policymakers in their collective efforts to combat the global health crisis.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call